clarithromycin has been researched along with famotidine in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (23.53) | 18.2507 |
| 2000's | 7 (41.18) | 29.6817 |
| 2010's | 6 (35.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Goh, KL; Parasakthi, N | 1 |
| Chuah, SY; Goh, KL; Lo, YL; Navaratnam, P; Peh, SC; Rahman, NA; Wong, NW | 1 |
| Jacoby, EB; Porter, KB | 1 |
| Brandstätter, G; Dragosics, B; Gschwantler, M; Hentschel, E; Hirschl, AM; Klimpfinger, M; Oberhuber, G; Pasching, E; Schütze, K; Weiss, W; Wimmer, M; Wurzer, H | 1 |
| Lam, EK; Lo, KY; Loo, CK; Mak, SK; Tong, GM; Wong, AK; Wong, AM; Wong, PN | 1 |
| Chan, CC; Chen, TK; Lee, CL; Liao, CC; Liu, CC; Tu, TC; Wu, CH | 1 |
| Bodrug, NI; Butorov, IV; Butorov, SI; Kirika, NV | 1 |
| Furuta, T; Miura, S; Okudaira, K; Shirai, N; Sugimoto, M | 1 |
| Fujioka, T; Inoue, K; Kodama, M; Miyajima, H; Murakami, K; Okimoto, T; Ono, M; Otsu, S; Sato, R; Watanabe, K | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
2 review(s) available for clarithromycin and famotidine
| Article | Year |
|---|---|
[Concomitant dosing of a H2 receptor antagonist (H2RA) with a triple therapy increases the cure rate of Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Enzyme Inhibitors; Famotidine; Gastric Acidity Determination; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Mixed Function Oxygenases; Omeprazole; Polymorphism, Genetic | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
6 trial(s) available for clarithromycin and famotidine
| Article | Year |
|---|---|
Primary and acquired resistance to clarithromycin among Helicobacter pylori strains in Malaysia.
Topics: Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Famotidine; Helicobacter Infections; Helicobacter pylori; Humans; Malaysia; Microbial Sensitivity Tests; Omeprazole | 1995 |
Helicobacter pylori eradication with short-term therapy leads to duodenal ulcer healing without the need for continued acid suppression therapy.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Famotidine; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Proton Pump Inhibitors; Treatment Outcome; Wound Healing | 1996 |
Famotidine versus omeprazole in combination with clarithromycin and metronidazole for eradication of Helicobacter pylori--a randomized, controlled trial.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Combinations; Drug Resistance, Microbial; Famotidine; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Stomach Ulcer | 1999 |
Maintenance treatment is not necessary after Helicobacter pylori eradication and healing of bleeding peptic ulcer: a 5-year prospective, randomized, controlled study.
Topics: Adult; Aged; Antacids; Anti-Ulcer Agents; Breath Tests; Carbolines; Clarithromycin; Drug Therapy, Combination; Famotidine; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Middle Aged; Omeprazole; Organometallic Compounds; Peptic Ulcer Hemorrhage; Prospective Studies; Secondary Prevention; Treatment Outcome | 2003 |
[Efficacy of different schemes of anti-helicobacter therapy in duodenal ulcer].
Topics: Adult; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Famotidine; Female; Helicobacter Infections; Helicobacter pylori; Humans; Josamycin; Male; Metronidazole; Treatment Outcome | 2004 |
Comparison of amoxicillin-metronidazole plus famotidine or lansoprazole for amoxicillin-clarithromycin-proton pump inhibitor treatment failures for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Famotidine; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Metronidazole; Middle Aged; Proton Pump Inhibitors; Proton Pumps; Treatment Failure | 2006 |
9 other study(ies) available for clarithromycin and famotidine
| Article | Year |
|---|---|
Helicobacter pylori infection and persistent hyperemesis gravidarum.
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Famotidine; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Hyperemesis Gravidarum; Omeprazole; Penicillins; Peptic Ulcer; Pregnancy; Pregnancy Complications, Infectious; Proton Pump Inhibitors; Ranitidine | 1999 |
Efficacy of a 1-week course of proton-pump inhibitor-based triple therapy for eradicating Helicobacter pylori in patients with and without chronic renal failure.
Topics: Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Famotidine; Female; Follow-Up Studies; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Kidney Failure, Chronic; Male; Middle Aged; Omeprazole; Peptic Ulcer; Prospective Studies; Proton Pump Inhibitors; Treatment Outcome | 2002 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |